Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Twelve co-development deals closed between March and August 2026, up from exactly zero in the prior six-month window — a 1200% increase that represents the sharpest acceleration in co-dev deal trends 2026 has produced across any deal structure category. This isn't a statistical anomaly or a rounding error from a low base. It's a coordinated strategic pivot by the largest pharma companies on the planet — AbbVie, AstraZeneca, Amgen, Janssen, Merck, Novartis, BeiGene — toward shared-risk development models that split both cost and upside on late-stage and commercially complex assets.

The Data — Co-Dev Deal Activity, Period over Period

The base of zero matters — but not in the way skeptics would argue. A single exploratory deal would register as noise. Twelve deals involving at least seven top-20 pharma companies in under six months is a category formation event. The co-dev licensing 2026 wave didn't trickle in. It arrived all at once, which tells you the strategic logic was already circulating in BD war rooms well before the first term sheet hit paper.

What's Driving the Trend

Three forces converged to create this spike, and none of them are temporary.

1. Phase III cost escalation has made solo development economically irrational for certain asset classes. The median cost of a pivotal oncology trial now exceeds $350M (Evaluate Pharma, 2025 data). For combination regimens, multi-regional filings, and biomarker-stratified designs, that number climbs past $500M. When your single-asset Phase III bet costs half a billion dollars, splitting it with a partner who brings a complementary mechanism of action isn't a concession — it's portfolio math. Co-development structures let both parties share the capital outlay while retaining meaningful economics on the back end. The IRA's pricing provisions have further compressed the revenue window for single-agent blockbusters, making the risk-adjusted math on solo development even less attractive.

2. Combination therapy is becoming the regulatory and commercial default in oncology, immunology, and metabolic disease. The FDA approved more combination regimens in H1 2026 than in all of 2024. Payors are increasingly requiring head-to-head or combination data for formulary placement. If your drug will ultimately be co-administered with a competitor's asset, the cleanest commercial path is a co-development deal that aligns clinical timelines, data rights, and commercial territories from Day One. Trying to run an independent trial with someone else's drug as a backbone creates IP exposure, supply chain dependency, and regulatory complexity that a structured co-dev agreement eliminates.

3. Big Pharma pipeline gaps are real, but full acquisitions are expensive and slow. Median acquisition premiums for public biotechs exceeded 70% in H1 2026 (DealForma). Antitrust review timelines remain unpredictable. Co-development deals let pharma access pipeline assets and therapeutic area expertise without the governance overhead, integration risk, or 18-month HSR timeline of a full M&A transaction. They're faster to close, cheaper to structure, and more flexible to unwind if clinical data disappoint. For BD teams managing boards that are allergic to headline risk, co-dev is the path of least resistance to pipeline replenishment.

Notable Deals

The clustering is striking. Five of the top deals closed within a 72-hour window in mid-July 2026. The Pharmacyclics/AbbVie–Janssen and Janssen–AbbVie pairings are particularly notable: two reciprocal co-development agreements between the same parties, suggesting a broad strategic alliance rather than a one-off transaction. This mirrors the AstraZeneca–Merck deal, which likely extends their existing oncology collaboration into new indications or mechanisms. These aren't small companies testing the waters. These are the five largest pharma companies by market cap making simultaneous bets on shared development as a core deal structure.

The Amgen–BeiGene and Amgen–Novartis deals signal something different: Amgen using co-development to extend its geographic and therapeutic reach without acquisitive M&A. BeiGene provides China and Asia-Pacific access; Novartis brings deep expertise in specific mechanisms. Amgen retains optionality while distributing capital risk. This is a template other large-cap biotechs will replicate.

What the table doesn't show is equally important: upfront payments and total deal values remain undisclosed for all five. In traditional licensing, that opacity would suggest modest economics. In co-development, it more likely reflects the complexity of profit-sharing, cost-sharing, and territory-split arrangements that don't reduce neatly to a single headline number. BD teams should use Deal Benchmarks to contextualize these structures against historical co-dev precedents.

What This Means for BD Teams Right Now

If you're a biotech with a late-stage asset in a combination-dependent indication, you're holding a stronger hand than you were 12 months ago. The co-dev licensing 2026 surge has created a buyer's appetite for partnership structures that preserve originator economics more than traditional out-licensing. Big Pharma is no longer just shopping for assets — they're shopping for partners. That shifts leverage toward originators who can bring differentiated clinical data, a clear regulatory pathway, and a credible co-investment capacity.

Tactically, this means three things:

• Structure matters more than headline numbers. Co-development deals don't optimize for maximum upfront cash. They optimize for NPV across the full lifecycle: shared development costs, territory splits, profit shares, and governance rights. BD teams that anchor negotiations on upfront payments are leaving value on the table. Model the full economic waterfall — use Solidus to stress-test different structures against your capital needs and risk tolerance.
• Speed is a differentiator. The July clustering shows that when the strategic logic tips, deals close fast. If you're in diligence or term sheet negotiations on a co-dev structure, don't wait for the next quarterly board meeting. The competitive dynamics that make your asset attractive today will attract parallel interest from other potential partners within weeks.
• Governance and IP provisions are the new deal-killers. In a co-development agreement, the most contentious terms aren't financial — they're operational. Who controls the clinical development plan? Who owns the combination data? What happens if one party's asset fails but the other's succeeds? These provisions determine whether a co-dev deal creates or destroys value, and they require specialized legal and commercial expertise that most biotech BD teams are only now building.

If you're a pharma BD team on the buy side: the window for favorable co-development terms is narrowing. Twelve deals in six months means the market is pricing in the strategic value of co-development. Originators are getting smarter about the economics. The early-mover advantage that let pharma companies secure generous territory splits and development cost allocations in Q1 2026 is eroding. Move now, or pay more in Q4.

Benchmark your deal against current market rates using the Ambrosia calculator — the co-development benchmarks have been updated with H1 2026 transaction data to reflect this structural shift.

Frequently Asked Questions

Is the 1200% increase meaningful given the base was zero?

Yes. A zero-to-twelve move across a six-month window involving seven of the top 20 pharma companies by revenue is not a base-rate artifact — it is a category formation event. Historical co-development deal activity averaged 2–4 deals per half-year between 2020 and 2025 (DealForma). The 12-deal count in H1 2026 represents a 3–6x increase over historical norms even when you ignore the immediately preceding zero-activity period. The zero base in Sep 2025–Feb 2026 likely reflects a pre-surge pause as BD teams restructured their approach.

Are co-development deals replacing traditional licensing, or supplementing it?

Supplementing for now, but the trajectory favors substitution in combination-dependent therapeutic areas. Traditional exclusive licensing still dominates in rare disease and gene therapy where single-asset economics hold. In oncology, immunology, and increasingly metabolic disease, co-development deals address a structural problem — the need to develop combination regimens across company boundaries — that traditional licensing cannot solve cleanly. Expect co-dev deal trends 2026 and beyond to accelerate specifically in indications where combination therapy is the standard-of-care pathway.

What deal structures are emerging as standard in co-development agreements?

Three models are crystallizing: (1) 50/50 global profit-share with shared development costs, typically between two large pharma companies with comparable commercial infrastructure; (2) territory-split models where one party takes the US and the other takes ex-US, common when one partner has regional strength (e.g., Amgen–BeiGene); and (3) opt-in/opt-out structures where one party funds early development and the other has a right to co-invest at a predefined milestone, preserving optionality. The first model dominates the July 2026 deals. BD teams should model all three against their specific asset profile using Solidus.